SCHEMBL6924758

SCHEMBL6924758

O=S(=O)(CC(F)(F)F)N1CCN(c2ccc(-c3nc(-c4ccc(F)cc4)c[nH]3)cn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.41
TDO2 P48775 4/20 0.39
RET P07949 1/20 0.38
CXCR3 P49682 3/20 0.38
HDAC10 Q969S8 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
SMO Q99835 1/20 0.37
MAPK1 P28482 1/20 0.37
DGAT1 O75907 2/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTR1A P08908 1/20 0.36
DRD4 P21917 1/20 0.36
HTR2A P28223 1/20 0.36
SLC6A4 P31645 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926613 0.85 TDO2 (0.41) PKMTDO2RETHDAC10HDAC1
SCHEMBL6928657 0.84 HTR1A (0.43) MAPK1KDM4ELMNAHTR1ADRD4
SCHEMBL6923542 0.83 MEN1 (0.44) PKMTDO2HDAC10MAPK1KDM4E
SCHEMBL6927606 0.80 KDM4E (0.55) PKMMAPK1KDM4ELMNAALDH1A1
SCHEMBL6926756 0.80 TDO2 (0.58) TDO2HDAC10DGAT1KDM4EALDH1A1
SCHEMBL6925946 0.79 TDO2 (0.45) TDO2RETKDM4ELMNAALDH1A1
SCHEMBL6927079 0.78 TDO2 (0.43) TDO2RETHDAC10HTR1ADRD4
SCHEMBL6924654 0.78 HDAC1 (0.50) TDO2RETHDAC10HDAC1HDAC6
SCHEMBL6923619 0.77 DRD3 (0.47) TDO2RETHDAC10HTR1ADRD4
SCHEMBL6925583 0.77 HTR2A (0.47) TDO2HTR1ADRD4HTR2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R PKM 2707/4885TDO2 1269/4885RET 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.